DK2086940T3 - Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol - Google Patents

Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Info

Publication number: DK2086940T3
Authority: DK; Denmark
Prior art keywords: alfa; beta; quinolinethanol; brom; naphthalenyl
Prior art date: 2006-12-05

Application number

DK07847697.5T

Other languages

English (en)

Inventor

Remoortere Peter Jozef Maria Van

Jean Francois Alexandre Lucas Hegyi

Wim Albert Alex Aelterman

Yolande Lydia Lang

Sigrid Carl Maria Stokbroekx

Carina Leys

Anne Faure

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-03

Publication date

2012-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2086940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2012-08-20 Application granted granted Critical

2012-08-20 Publication of DK2086940T3 publication Critical patent/DK2086940T3/da

Links

MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical class C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 title 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK07847697.5T 2006-12-05 2007-12-03 Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol DK2086940T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06125443		2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en)	2006-12-05	2007-12-03	Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number	Publication Date
DK2086940T3 true DK2086940T3 (da)	2012-08-20

Family

ID=37983588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07847697.5T DK2086940T3 (da)	2006-12-05	2007-12-03	Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Country Status (34)

Country	Link
US (1)	US8546428B2 (da)
EP (1)	EP2086940B1 (da)
JP (2)	JP2010511663A (da)
KR (1)	KR101514700B1 (da)
CN (2)	CN101547904A (da)
AP (1)	AP2498A (da)
AR (1)	AR064149A1 (da)
AU (1)	AU2007328945B2 (da)
BR (1)	BRPI0719693A2 (da)
CA (1)	CA2668512C (da)
CL (1)	CL2007003472A1 (da)
CY (1)	CY1113594T1 (da)
DK (1)	DK2086940T3 (da)
EA (1)	EA017091B9 (da)
ES (1)	ES2387923T3 (da)
HK (1)	HK1214513A1 (da)
HR (1)	HRP20120639T1 (da)
IL (1)	IL199077A (da)
JO (1)	JO2973B1 (da)
ME (1)	ME01456B (da)
MX (1)	MX2009005909A (da)
MY (1)	MY148844A (da)
NO (1)	NO342773B1 (da)
NZ (1)	NZ576485A (da)
PE (1)	PE20081350A1 (da)
PL (1)	PL2086940T3 (da)
PT (1)	PT2086940E (da)
RS (1)	RS52408B (da)
SI (1)	SI2086940T1 (da)
TW (1)	TWI417098B (da)
UA (1)	UA97813C2 (da)
UY (1)	UY30762A1 (da)
WO (1)	WO2008068231A1 (da)
ZA (1)	ZA200903907B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120010216A1 (en) *	2010-07-06	2012-01-12	Brown Arthur M	Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) *	2014-10-16	2016-04-27	Zentiva, K.S.	Soli Bedaquilinu
CN114129526A (zh) *	2015-01-27	2022-03-04	詹森药业有限公司	可分散组合物
CN106279017A (zh) *	2015-05-21	2017-01-04	重庆圣华曦药业股份有限公司	贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) *	2015-06-09	2016-12-21	Zentiva, K.S.	Sůl bedaquilinu s kyselinou citronovou
US10196360B2 (en)	2015-10-20	2019-02-05	Zhejiang Hisun Pharmaceutical Co., Ltd.	Crystal forms of bedaquiline fumarate and preparation methods therefor
JP7030776B2 (ja) *	2016-07-20	2022-03-07	ノバルティスアーゲー	アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
CN106316943A (zh) *	2016-07-27	2017-01-11	重庆华邦制药有限公司	富马酸贝达喹啉晶型化合物的精制方法
WO2019012100A1 (en)	2017-07-14	2019-01-17	Janssen Pharmaceutica Nv	EXTENDED ACTION FORMULATIONS
WO2020123336A1 (en) *	2018-12-13	2020-06-18	Qrumpharma Inc.	Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
KR20210113628A (ko)	2019-01-09	2021-09-16	얀센 파마슈티카 엔.브이.	비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2020161743A1 (en) *	2019-02-08	2020-08-13	Mylan Laboratories Limited	Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) *	2020-07-01	2021-09-17	동아에스티 주식회사	(1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) *	2020-09-15	2023-03-07	北京福元医药股份有限公司	一种贝达喹啉药物制剂
KR20230107275A (ko)	2020-11-12	2023-07-14	얀센 파마슈티카 엔.브이.	비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
US11793808B2 (en)	2021-02-22	2023-10-24	Mannkind Corp.	Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en)	2022-02-07	2023-08-10	Insmed Incorporated	Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en)	2022-05-31	2023-12-07	Janssen Pharmaceutica Nv	Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) *	2022-07-07	2025-06-24	上海交通大学	含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3237575A1 (de) *	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
GB8824392D0 (en) *	1988-10-18	1988-11-23	Ciba Geigy Ag	Dispersible formulation
TW355683B (en) *	1994-02-17	1999-04-11	Janssen Pharmaceutica Nv	Composition containing micronized nebivolol
US5965572A (en)	1996-10-28	1999-10-12	The United States Of America As Respresented By The Secretary Of The Army	Methods for treating antibiotic-resistant infections
CZ341297A3 (cs) *	1996-10-30	1998-05-13	Eli Lilly And Company	Způsob zlepšení léčby nebo profylaxe rakoviny prsu
US6819464B2 (en) *	2002-06-19	2004-11-16	Seiko Epson Corporation	Optical modulator, optical device and projector
PT1527050E (pt) *	2002-07-25	2010-06-22	Janssen Pharmaceutica Nv	Derivados de quinolina e sua utilização como inibidores de micobactérias
AU2002350719A1 (en) *	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JO2524B1 (en) *	2004-05-28	2010-03-17	جانسن فارمسيتكا ان في	Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
WO2006024667A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
KR101301573B1 (ko) *	2004-12-24	2013-09-04	얀센 파마슈티카 엔.브이.	잠재성 튜버큐로시스의 치료법

2007
- 2007-03-12 UA UAA200904218A patent/UA97813C2/uk unknown
- 2007-12-02 JO JO2007511A patent/JO2973B1/en active
- 2007-12-03 DK DK07847697.5T patent/DK2086940T3/da active
- 2007-12-03 JP JP2009539724A patent/JP2010511663A/ja active Pending
- 2007-12-03 RS RS20120336A patent/RS52408B/sr unknown
- 2007-12-03 AP AP2009004870A patent/AP2498A/xx active
- 2007-12-03 PL PL07847697T patent/PL2086940T3/pl unknown
- 2007-12-03 AU AU2007328945A patent/AU2007328945B2/en active Active
- 2007-12-03 ME MEP-2012-95A patent/ME01456B/me unknown
- 2007-12-03 NZ NZ576485A patent/NZ576485A/en unknown
- 2007-12-03 HR HRP20120639TT patent/HRP20120639T1/hr unknown
- 2007-12-03 WO PCT/EP2007/063186 patent/WO2008068231A1/en not_active Ceased
- 2007-12-03 EA EA200970532A patent/EA017091B9/ru active Protection Beyond IP Right Term
- 2007-12-03 CN CNA2007800448088A patent/CN101547904A/zh active Pending
- 2007-12-03 MY MYPI20092284A patent/MY148844A/en unknown
- 2007-12-03 KR KR1020097011043A patent/KR101514700B1/ko active Active
- 2007-12-03 ES ES07847697T patent/ES2387923T3/es active Active
- 2007-12-03 US US12/515,986 patent/US8546428B2/en active Active
- 2007-12-03 BR BRPI0719693-8A2A patent/BRPI0719693A2/pt not_active Application Discontinuation
- 2007-12-03 PT PT07847697T patent/PT2086940E/pt unknown
- 2007-12-03 MX MX2009005909A patent/MX2009005909A/es active IP Right Grant
- 2007-12-03 EP EP07847697A patent/EP2086940B1/en active Active
- 2007-12-03 CL CL200703472A patent/CL2007003472A1/es unknown
- 2007-12-03 CA CA2668512A patent/CA2668512C/en active Active
- 2007-12-03 SI SI200730984T patent/SI2086940T1/sl unknown
- 2007-12-03 CN CN201510368829.1A patent/CN105012303A/zh active Pending
- 2007-12-04 TW TW096146000A patent/TWI417098B/zh active
- 2007-12-05 AR ARP070105442A patent/AR064149A1/es not_active Application Discontinuation
- 2007-12-05 UY UY30762A patent/UY30762A1/es active IP Right Grant
- 2007-12-05 PE PE2007001719A patent/PE20081350A1/es active IP Right Grant
2009
- 2009-06-02 IL IL199077A patent/IL199077A/en active IP Right Grant
- 2009-06-04 ZA ZA2009/03907A patent/ZA200903907B/en unknown
- 2009-07-06 NO NO20092535A patent/NO342773B1/no unknown
2012
- 2012-08-13 CY CY20121100734T patent/CY1113594T1/el unknown
2014
- 2014-09-19 JP JP2014191134A patent/JP5894239B2/ja active Active
2016
- 2016-03-04 HK HK16102481.4A patent/HK1214513A1/zh unknown

Also Published As

Publication number	Publication date
JP2010511663A (ja)	2010-04-15
RS52408B (sr)	2013-02-28
WO2008068231A1 (en)	2008-06-12
AP2009004870A0 (en)	2009-06-30
ME01456B (me)	2014-04-20
PE20081350A1 (es)	2008-09-18
KR20090087020A (ko)	2009-08-14
UY30762A1 (es)	2008-07-03
ES2387923T3 (es)	2012-10-04
MY148844A (en)	2013-06-14
IL199077A (en)	2016-09-29
JO2973B1 (en)	2016-03-15
NO342773B1 (no)	2018-08-06
JP5894239B2 (ja)	2016-03-23
CL2007003472A1 (es)	2008-08-22
PT2086940E (pt)	2012-08-09
NZ576485A (en)	2012-01-12
MX2009005909A (es)	2009-06-16
EP2086940B1 (en)	2012-05-16
HK1214513A1 (zh)	2016-07-29
KR101514700B1 (ko)	2015-04-24
US8546428B2 (en)	2013-10-01
AP2498A (en)	2012-10-19
SI2086940T1 (sl)	2012-09-28
TW200838527A (en)	2008-10-01
CY1113594T1 (el)	2016-06-22
AR064149A1 (es)	2009-03-18
US20100028428A1 (en)	2010-02-04
EA017091B1 (ru)	2012-09-28
EP2086940A1 (en)	2009-08-12
UA97813C2 (uk)	2012-03-26
ZA200903907B (en)	2013-08-28
CA2668512C (en)	2015-03-24
BRPI0719693A2 (pt)	2013-12-24
EA200970532A1 (ru)	2009-10-30
CA2668512A1 (en)	2008-06-12
CN101547904A (zh)	2009-09-30
HRP20120639T1 (hr)	2012-08-31
JP2015028049A (ja)	2015-02-12
TWI417098B (zh)	2013-12-01
EA017091B9 (ru)	2014-10-30
AU2007328945B2 (en)	2014-04-03
NO20092535L (no)	2009-08-06
PL2086940T3 (pl)	2012-10-31
AU2007328945A1 (en)	2008-06-12
CN105012303A (zh)	2015-11-04

Publication	Publication Date	Title
DK2101570T3 (da)	2013-05-27	Tannatsalt af rasagilin
AP2498A (en)	2012-10-19	Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
DE502008000295D1 (de)	2010-02-25	Nockenwelle
DE112007002915A5 (de)	2009-10-15	Verstelleinrichtung
DE502007002976D1 (de)	2010-04-15	Nockenwelle
EP1998019A4 (en)	2013-03-27	THERMOSTAT
ATE449068T1 (de)	2009-12-15	Neue mikrobiozide
DE502007001122D1 (de)	2009-09-03	Humeruskomponente
DK2114147T3 (da)	2012-06-25	Reduktion af bivirkninger af tramadol
PT2223114T (pt)	2016-09-29	Calibrante para imunoensaios
FR2908035B1 (fr)	2009-05-01	Implant interepineux
DE112007000221A5 (de)	2009-01-15	Abseilvorrichtung
EP2081471A4 (en)	2011-07-13	MAGNETIC GOGGLES
BRPI0813781A2 (pt)	2019-09-24	microbiocidas
ATE523493T1 (de)	2011-09-15	2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
DK2054363T3 (da)	2013-06-03	Asymmetrisk hydrogenering af 1,1,1-trifluoracetone
SE0602723L (sv)	2007-12-17	Belagt skär
DE602007002163D1 (de)	2009-10-08	Weichspülmittel
DK2089708T3 (da)	2012-12-03	Forudsigelige kræft-immunterapi parametre
DK2046745T3 (da)	2014-01-20	Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
DE602007011413D1 (de)	2011-02-03	Phasenregelkreiselement
DE502006007220D1 (de)	2010-07-29	Nockenwelle
ITVI20060074A1 (it)	2007-09-18	Struttura di ancoraggio,particolarmente per radiatori
FI20065528A0 (fi)	2006-08-25	Moniresonanssiantenni
ITMI20060760A1 (it)	2007-10-15	Procedimento per il trattamento di tessuti